An unusual finding from fecal immunochemical testing: A case report
Issue: BCMJ,
vol. 62 , No. 5 , June 2020 ,
Pages 166-169 Clinical Articles
ABSTRACT: This case report describes the presentation, workup, and management of a 73-year-old patient with multifocal extranodal mucosa-associated lymphoid tissue (MALT) lymphoma. The MALT lymphoma was identified through a process that began with routine fecal immunochemical testing, which is recommended in BC for screening average-risk patients for colorectal cancer. The fecal immunochemical test (FIT) used for screening requires the patient to submit a stool sample collected at home using a simple kit. The sample is then analyzed for the presence of blood. However, because bleeding can occur with benign pathologies such as hemorrhoids, inflammatory bowel disease, and vascular lesions, further investigation is required when certain pathologies are found on colonoscopy done in the colon screening program. In this case, investigation included esophagograstroduodenoscopy and CT imaging. The results from all investigations eventually led to the detection of a rare gastric cancer. Despite the patient being from a part of the world with high rates of endemic Helicobacter pylori, the MALT lymphoma identified was not associated with H. pylori and was probably related to a systemic inflammatory disorder.
Endoscopic and histologic investigations following a positive fecal immunochemical test (FIT) result eventually led to the detection of a rare mucosa-associated lymphoid tissue (MALT) lymphoma.
Case data
A 73-year-old female with average risk of colon cancer presented for routine fecal immunochemical testing. She had been screened in the past with the fecal immunochemical test (FIT). Her medical history was significant for a cerebrovascular accident, dyslipidemia, osteoporosis, and an inflammatory spondyloarthropahy with inflammatory sacroiliitis. Her medications included ASA, alendronate, and naproxen as needed. She was a nonsmoker with no alcohol consumption and had moved to Canada from Hong Kong. She had a second-degree relative diagnosed after age 60 with colorectal cancer.
After having negative FIT results in 2014 and 2015, the patient had a positive FIT result in July 2018 with a value of 171 ng/mL. When assessed prior to colonoscopy, she reported no hematochezia or melena and regular bowel movements with no change in her bowel habits. She had no early satiety, epigastric pain, nausea, or vomiting. Her weight was stable. She had no fevers, chills, or night sweats. Physical examination revealed no abdominal masses or peripheral lymphadenopathy.
Her colonoscopy revealed a 1-cm pedunculated polyp in the ascending colon and two 5-mm semi-pedunculated polyps in the transverse colon. Evidence of mild colitis was found in the rectosigmoid region and tissue was obtained for biopsy [Figure 1]. Retroflexion in the rectum revealed only internal hemorrhoids. The ascending colon polyp was a tubulovillous adenoma with low-grade dysplasia. The transverse polyps were a sessile serrated adenoma without dysplasia and a tubular adenoma with low-grade dysplasia.
Histologic sections of the rectosigmoid biopsies revealed an atypical lymphoid infiltrate that had expanded the lamina propria and replaced the glands [Figure 2]. Scattered lymphoepithelial lesions were identified. Immunohistochemistry demonstrates an atypical B cell population positive for CD20 and negative for CD3, CD5, CD10, and CD43. A lambda light chain restriction was observed. The findings were consistent with low-grade B cell mucosa-associated lymphoid tissue (MALT) lymphoma.
The patient underwent an esophagograstroduodenoscopy (EGD) that revealed atrophic gastric mucosa in the proximal stomach. Erythema with an abnormal mucosal pattern was seen from the mid-gastric body extending into the antrum, pylorus, and first part of the duodenum [Figure 3]. Biopsies of the gastric and duodenal mucosa again showed a clonal population of CD20 lymphocytes with lambda light chain restriction and confirmed the diagnosis of extranodal marginal zone MALT lymphoma [Figure 4].
Other investigations revealed the patient’s hemoglobin level was 117 g/L, her WBC was 3.5 × 109/L, and her platelet count was 163 × 109/L. The patient was also found to have a lactate dehydrogenase (LDH) level of 187 IU/L, creatinine of 74 μmol/L, and beta-2 microglobulin of 2.4 mcg/mL. Her serum protein electrophoresis showed a monocloncal IgM lambda band in the beta 2 region. Helicobacter pylori, bacteria endemic in the patient’s area of origin and typically associated with this lymphoma, were not identified by biopsy or by a urea breath test. A bone marrow biopsy showed no bone involvement. A CT scan showed abnormal wall thickening in the gastric antrum, proximal duodenum, and lower rectum [Figure 5]. There were prominent subcentimetre lymph nodes near the stomach and rectosigmoid.
The patient was followed by her oncologist and a repeat EGD and colonoscopy were done at 6 months and found to show no endoscopic or histologic changes. Currently the patient remains on an active surveillance schedule and is receiving no therapy as she is asymptomatic and has a good performance status.
Discussion
Extranodal mucosa-associated lymphoid tissue lymphomas are induced by chronic inflammation,[1] with MALT lymphoma being the most common of marginal zone B cell lymphomas.[2] The prototypical infection for MALT involvement of the stomach is H. pylori. A study published in 2010 found the incidence of H. pylori-associated MALT lymphoma has declined[3] compared with an earlier study that found H. pylori infection in 92% of all gastric MALT lymphomas considered.[4]
US data indicate that extranodal marginal zone lymphoma is rare, with 18.3 cases per 1 million person years, and that the median age at diagnosis is 66 years.[5] The stomach is the most frequent site of involvement, but MALT can also involve the colon, salivary glands, ocular adenexa, lungs, thyroid, breast, and liver.[6] Symptoms can include reflux, epigastric pain, anorexia, weight loss, and gastrointestinal bleeding.[7] Monoclonal gammopathy is found in 27% to 36% of patients.[8]
This case is interesting because the diagnosis was made with the help of the BC Cancer Colon Screening Program, which identifies those at risk of colon cancer using the FIT—a simple test that requires patients to provide a stool sample for analysis. If blood is detected, follow-up procedures are ordered. This case is also interesting because the patient had multifocal disease with involvement of the stomach, small bowel, and rectosigmoid, yet had no evidence of H. pylori infection. Besides H. pylori infection, autoimmune diseases such as systemic lupus erythematous, Sjögren’s syndrome, Hashimoto disease, and relapsing polychondritis have been associated with MALT.[1,9,10] This patient had inflammatory spondyloarthropahy with inflammatory sacroiliitis. The mechanism postulated in cases such as this is that chronic inflammation leads to the local accumulation and proliferation of antigen-dependent B cells and T cells. B cell clones will remain that still depend on the antigen-stimulated immune response for growth and survival. With acquisition of additional mutations, the tumor becomes antigen-independent and capable of systemic spread.[11]
Historically, the Lugano staging system was used for gastrointestinal lymphomas, but models such as the Paris Staging System[12] can also be used. This patient was designated stage IV as she had disseminated extranodal involvement in multiple areas of the gastrointestinal tract.
In H. pylori-associated cases, bacteria eradication therapy should be prescribed regardless of disease stage.[1,12] Eradiation of the bacteria should then be documented with a breath test.[13] The decision to use rituximab, chemotherapy, or radiation is dependent on symptoms and disease distribution.[12] Long-term follow-up with physical examinations, blood testing (including a CBC), cross-sectional imaging, and endoscopy should be implemented to monitor for progression and transformation.[12]
Summary
In the case described here a 73-year-old female was diagnosed with mucosa-associated lymphoid tissue lymphoma after a process that began with routine fecal immunochemical testing. A positive FIT result led to the patient undergoing colonoscopy, esophogastrodenoscopy, blood testing, and CT imaging. Although the patient was not found to have H. pylori-associated disease, she did have inflammatory spondyloarthropahy with inflammatory sacroiliitis. Her systemic inflammatory disorder may have been a factor in her MALT diagnosis, since extranodal mucosa-associated lymphoid tissue lymphomas are known to be induced by chronic inflammation.
The stomach is the most common site affected, but MALT lymphoma can also involve the colon, salivary glands, ocular adenexa, lungs, thyroid, breast, and liver. Symptoms may include reflux, epigastric pain, anorexia, weight loss, and gastrointestinal bleeding. Once identified, treatment of MALT lymphoma may include H. pylori-eradication therapy, chemotherapy, or radiation. In this case, the patient is currently asymptomatic and remains on an active surveillance schedule without therapy. The patient was referred for a radiation oncology opinion for symptom management or to delay the need for systemic therapy. She was offered radiation to the gastric lesion, but declined treatment due to lack of symptoms and concern around the side effects of radiation.
Competing interests
None declared.
This article has been peer reviewed.
References
1. Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: Biological and therapeutic relevance. Blood 2016;127:2082-2092.
2. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the surveillance, epidemiology, and end results database. Cancer 2013;119:629-638.
3. Luminari S, Cesaretti M, Marcheselli L, et al. Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: Results from a population-based study on extranodal marginal zone lymphomas. Ann Oncol 2010;21:855-859.
4. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338(8776):1175-1176.
5. Khalil MO, Morton LM, Devesa SS, et al. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol 2014;165:67-77.
6. Zucca E, Conconi A, Pedrinis E, et al.; International Extranodal Lymphoma Study Group. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-2495.
7. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German multicenter study GIT NHL 01/92. J Clin Oncol 2001;19:3861-3873.
8. Wöhrer S, Streubel B, Bartsch R, et al. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res 2004;10:7179-7181.
9. Ramos-Casals M, la Civita L, de Vita S, et al. Characterization of B cell lymphoma in patients with Sjögren’s syndrome and hepatitis C virus infection. Arthritis Rheum 2007;571:161-170.
10. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-4038.
11. Park YK, Choi JE, Jung WY, et al. Mucosa-associated lymphoid tissue (MALT) lymphoma as an unusual cause of malignant hilar biliary stricture: A case report with literature review. World J Surg Oncol 2016;14:167.
12. Zucca E, Copie-Bergman C, Ricardi U, et al. ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(suppl 6):vi144-vi148.
13. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016;151:51-69.
Dr Sanders is a gastroenterology resident at the University of British Columbia and is based at Vancouver General Hospital. Dr Yang is a consultant pathologist at Vancouver General Hospital and an associate clinical professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. Dr Gan is a gastroenterologist at Vancouver General Hospital and an associate professor in the Division of Gastroenterology at the University of British Columbia.